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Abstract
The VEGFs -A, -B, -C, -D are important signaling molecules with pivotal implication 
in the growth of blood and lymphatic vessels, the so-called angio- and
lymphangiogenesis. They exert their activities by binding to their receptors, 
VEGFRs-1, -2 and -3. Their involvement in pathologic processes such as tumor 
growth or inflammatory disorders has been thoroughly described, rheumatoid arthritis 
being just one example. The VEGF family represents the link between angiogenesis 
and bone turnover, as seen in cancer metastasis to the bone or arthritis. Furthermore, 
they are involved in the differentiation of dendritic cells and lymphocytes, while 
macrophages and PMNs have been identified as sources of VEGFs, showing a 
mediatory function of these molecules in immune responses.
The presence of VEGF-A and its main angiogenic receptor VEGFR-2 in well-
vascularized normal dental pulp has been previously described. Apical periodontitis, 
a common inflammatory disease caused by the interaction of root canal bacteria with 
the host immune response, is characterized by bone resorption. VEGF-A is also 
known to be present in these lesions of endodontic origin. 
However, the picture of VEGF family and their receptors with respect to location and 
function in the dental pulp and in periapical pathology have so far been incomplete. 
The aims of this thesis were to identify and map the presence of VEGF family and 
their receptors VEGFR-2 and -3 in apical periodontitis and dental pulp and to 
investigate their role in periapical disease development. 
In normal rat apical periodontium (Paper I), VEGF-A, -C, -D and VEGFR-2 and -3
were present on blood vessels. Upon endodontic exposure for periapical disease 
development, an intensification of immunohistochemically stained vascular structures 
was noticed. Macrophages and neutrophils expressed all VEGFs and VEGFRs in the 
lesions, with macrophages being an important source of VEGF-C and -D. Osteoclasts 
were the source for VEGFR-2 and -3. The gene expression of VEGF-A and VEGFR-
3 was significantly up-regulated following pulp exposure. The results suggest the 
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implication of VEGF family and their receptors in the periapical immune response, 
vascular remodeling and in bone resorptive activities.
In human periapical lesions (Paper II) VEGFs and VEGFRs were expressed on blood 
vessels and on macrophages, PMNs, B- and T-lymphocytes. At the gene level, 
significant up-regulations were recorded for genes involved in VEGF-mediated 
angiogenic activity, such as phosphatidylinositol-3-kinases (Pl3K), protein kinase C
(PKC), mitogen-activated protein kinases (MAPK) and phospholipases (PL). These 
findings suggest the implication of VEGF family in ongoing immune reactions along 
with vascular remodeling in human established periapical lesions.
The normal dental pulp (Paper III) presented with blood vessels, macrophages and T-
lymphocytes positive for the same VEGFs and VEGFRs. Furthermore, VEGF-B was
only seen at cellular level in the dental pulp. Twenty-six of 84 VEGF signaling genes, 
including VEGFR-3 were significantly altered in the dental pulp compared with 
control PDL. The pulpal tissue has high VEGF signaling capacity with respect to 
immune responses and vascular activity.
Using specific markers for lymphatic vessels, we confirmed the absence of lymphatic 
vessels from both apical periodontium and the dental pulp. Macrophages expressing 
LYVE-1 were found in human periapical lesions and the dental pulp, with an 
assumed angiogenic role.
Upon inducing periapical lesions we systemically blocked VEGFR-2 and/or -3 in 
order to investigate their signaling patterns with respect to lesion size, angiogenesis, 
local inflammatory response and lymphangiogenesis in the draining lymph nodes 
(Paper IV). We have found that VEGFR-2 reduces inflammation whereas combined 
VEGFR-2 and -3 signaling causes an increase of the process, seen in amounts of 
PMNs and osteoclasts, as well as different cytokines expression. In the regional 
lymph nodes, lymphangiogenesis is dependent on VEGFR-2 and/or VEGFR-3
signaling.
The results of these studies provide evidence on the presence of VEGFs and VEGFRs 
in dental pulp and apical periodontitis, with implications in immune responses and 
vascular remodeling. VEGFR-2 and/or -3 signaling influences inflammatory 
reactions during periapical disease development.
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1.1 Vascular endothelial growth factors (VEGFs) and 
receptors (VEGFRs)
First organ system to develop during embryogenesis is the circulatory system. The 
major regulators of blood and lymphatic vessel development are the members of the 
vascular endothelial growth factor (VEGF) family. The initial formation of the 
primitive vascular plexus is known as vasculogenesis [1], whereas the process of 
blood and lymphatic vessel development from preexisting vessels, as occurring in 
adult tissues, is known as angio- and lymphangiogenesis, respectively. The essential 
cells from which the vessels are built are the endothelial cells (ECs) [2].
The VEGF family in mammals includes five glycoproteins: VEGF-A (or 
VEGF/vascular permeability factor), VEGF-B, VEGF-C, VEGF-D and placental 
growth factor (PlGF) [3]. These bind with differing affinities to three endothelial 
transmembrane tyrosine kinase receptors, the VEGFRs: VEGFR-1 (Flt1), VEGFR-2
(human KDR/mouse Flk1) and VEGFR-3 (Flt4). Neuropilins (NRP-1 and NRP-2) 
can also work as co-receptors to the various VEGFRs in ECs [4].
VEGF-A is essential for development of blood vessels and exerts this activity via 
VEGFR-2, but is also to bind VEGFR-1, as well as NRP-1 and NRP-2 [5]. The
angiogenic effect is mainly driven by VEGFR-2, while VEGFR-1 acts as a negative 
regulator of the process [6].
Under physiologic conditions, ECs in adult organisms are mostly quiescent. 
Exceptions, during which VEGF-A and its receptors increase in expression, include
exercise-induced angiogenesis in heart and skeletal muscle [7], the hair cycle [8], the 
female reproductive cycle and placental growth [9] and wound healing [10]. VEGF-A
mostly exerts its’ activities on ECs, but it can also bind to its’ receptors on 
hematopoietic stem cells, neurons or monocytes [11]. Osteoblasts and chondrocytes 
produce VEGF-A [12, 13], linking it to skeletal growth and endochondral bone 
formation [14, 15]. The presence of VEGFR-2 on both osteoblasts and osteoclasts 
indicates the involvement of VEGF-A in bone remodeling [16]. Activation of 
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angiogenesis starts as VEGF-A engages with VEGFR-2 thereby inducing the 
proliferation, survival, sprouting and migration of ECs and increasing endothelial 
permeability [3].
Under homeostatic conditions, VEGF-B is highly expressed in heart myocardium, 
skeletal muscle, brown fat, vascular smooth muscle, brain, kidney and parietal cells 
of the stomach [17-20], while PlGF is found in placenta, heart, lungs, skeletal muscle 
and adipose tissue [21-23]. Both are specific ligands to VEGFR-1 [3, 24], but can 
also transduce their signals via NRP-1 [25]. While PlGF has an angiogenic role [26, 
27], VEGF-B seems to be related to metabolic functions [28, 29] neuroprotection [30]
and primarily connected to inflammatory settings [31].
VEGF-C and -D normally bind to VEGFR-3 and are responsible for lymphatic vessel 
development. However, upon proteolytic activation, VEGF-C and -D also bind to
VEGFR-2, thus being involved in angiogenic, as well as lymphangiogenic activities 
[32]. NRP-2 is a co-receptor for both VEGF-C and -D and required for efficient 
sprouting of lymphatic capillaries [33]. During embryogenesis, VEGF-C is expressed 
around areas of lymphatic development, along with its receptor VEGFR-3 [34, 35].
The expression decreases thereafter, however remaining high in lymph nodes [36].
VEGF-D is expressed in various locations in murine embryos, while in humans it is 
strongly detected in skeletal muscle, colon, small intestine, heart and lung [37-39].
Although VEGF-C is essential for lymphatic development, VEGF-D seems to be 
dispensable, with uncertain physiological role during embryogenesis, as seen in 
knockout mice models [40]. VEGFR-3 is widely expressed in ECs during mouse 
embryogenesis, but later on it is mostly restricted to lymphatic endothelium [41, 42].
It seems to also play a role in mouse embryonic angiogenesis [43]. In human adult 
tissues, VEGFR-3 is mostly found on lymphatic ECs, exerting a protective role at this 
level, but could also be identified on fenestrated blood capillaries [44], monocytes, 
macrophages and some dendritic cells [45, 46]. Figure 1 gives an overview of VEGF 
family and their binding affinities to different receptors.
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Figure 1. Schematic representation of VEGF binding affinities to the different 
receptors and their involvement in angio- and lymphangiogenesis. VEGF-A is the 
main angiogenic factor. VEGF-C and -D transduce lymphangiogenic signals, and 
upon proteolytic activation bind to both VEGFR-2 and -3, thus also promoting 
angiogenesis. 
1.2 Blood and lymphatic vasculature
The vascular system must supply tissues with nutrients, growth factors and hormones 
as well as clear waste products. 
Therefore, a certain vascular permeability is required in order to allow small 
molecules to extravasate under homeostatic conditions. [47]. Lymphatic ECs (LECs),
just like blood ECs (BECs) are also quiescent under resting conditions. During 
homeostasis, lymphatics are essential for regulation of interstitial pressure, lipid 
metabolism and immune surveillance [48]. They absorb water and macromolecules 
from the interstitium, uptake vitamins and lipids in the intestine and provide an 
important traffic route for immune cells [49]. Lymphatics start as blind-ended vessels 
in the interstitium and have the primary aim to drain excess interstitial fluid, returning 
it into the blood stream. Hereby, the lymph passes through collecting ducts and 
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lymph nodes, and in the latter scanning for foreign antigens occurs – hence the 
importance of the lymphatic system for the immune defense [24].
Figure 2. Lymphatic vessels collect macromolecules, cells and fluid provided by 
blood vessels from the interstitium (a, modified image from Servier Medical Art, 
Laboratoires Servier, Suresnes, FR). These enter the lymphatic capillaries via valve-
like structures between the LECs. These portals also prevent the return of lymph to 
the intersitium (b). The anchoring filaments attach the ECs to the extracellular matrix 
(ECM) and also prevent the collapse of vessels under conditions of increased tissue 
pressure (c).
1.2.1 Distinguishing blood from lymphatic vasculature
Lymphatic and blood capillaries are structurally different. With the exception of 
fenestrated and discontinuous endothelia, BECs interconnect via tight junctions, 
resulting in a continuous basement membrane. In contrast, lymphatic capillaries lack 
the surrounding connective tissue cells of the blood vessels, the pericytes, and present 
with loosely connected LECs and a discontinuous basement membrane. The LECs
attach to the ECM via anchoring filaments [50], which regulate the valve-like
opening of the ECs in the lymphatic lumen [48]. These portals allow fluid, particles
and immune cells, such as dendritic cells and some leukocytes, to enter the vessel 
lumen [51-53] (Figure 2).
Both BECs and LECs carry pan-endothelial markers, such as Platelet endothelial cell 




lymphatics [54]. The differentiation can be difficult regarding their VEGFRs 
expression. BECs express VEGFRs-1 and -2, while VEGFRs-2 and -3 are found on 
LECs. Furthermore, VEGFR-3 is also expressed by fenestrated blood endothelium, 
high endothelial venules (HEVs) of the lymph nodes, as well as abnormal tumor 
vessels [41, 44, 55]. LECs are intensely positive for specific molecules, such as 
prospero homebox-1 (Prox1), the membrane glycoprotein podoplanin (D2-40) and 
lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) [34, 56-59], which can 
be used in order to distinguish between BECs and LECs. A selection of blood- and 
lymphatic markers is presented in figure 3.
Figure 3. Selected markers for blood and lymphatic endothelium, reviewed in [60]
(BEC, blood endothelial cell; LEC, lymphatic endothelial cell). ”+”sign represents 
staining intensity. 
1.2.2 Angio- and lymphangiogenesis in disease
ECs maintain the ability to divide and proliferate in response to different stimuli, such 
as hypoxia (insufficient oxygen concentration), often found during tissue expansion. 
Activation of hypoxia-inducible factor (HIF), especially HIF-1 , stimulates vasculo-
and angiogenesis through induction of VEGF-A. However, hypoxia is also 
characteristic of both inflammation and cancer [61, 62]. Ferrara N. [63] reported that 
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hormones, several growth factors, inflammatory cytokines and oncogenes can induce 
VEGF-A expression in various tissues and cells. Consequently, excessive 
angiogenesis is used as a hallmark of many disorders – cancer, chronic inflammations 
like arthritis [64] or psoriasis [65], atherosclerosis [66, 67], infectious diseases [68, 
69], diabetic retinopathy [70], asthma [71] or obesity [72] (Table 1).
Table 1. Diseases related to abnormal and increased angiogenesis, modified after 
Carmeliet P. [73].
The VEGF family and their receptors have been identified in a variety of immune 
cells involved in different disorders. Mast cells, which infiltrate chronic inflammatory 
sites and tumors, can express VEGF-A, -B, -C and -D and enhance the expression of 
VEGF-A [74]. VEGF-A induces monocyte migration through the activation of 
VEGFR-1 [75]. Monocytes, progenitor cells of macrophages and dendritic cells, 
express VEGFR-1 in a high majority [76], whereas PlGF, ligand to VEGFR-1,




Infectious diseases, including 
periodontal disease
Blood vessels Atherosclerosis, hemangiomas
Skin Warts, pyogenic granulomas, 
psoriasis, Kaposi’s sarcoma,  scar 
keloids
Female reproductive system Endometriosis, uterine bleeding, 
ovarian cysts/hyperstimulation
Adipose tissue Obesity
Bone, joints Rheumatoid arthritis, synovitis, 
osteomyelitis
Eye Prematurity - and diabetic retinopathy
Digestive system Inflammatory bowel disease, ascites
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induces cytokine and chemokine gene expression in these cells [77]. Macrophage 
colony stimulating factor (M-CSF), a pro-inflammatory cytokine, can induce VEGF-
A expression by monocytes [78], suggestive of the angiogenic role of monocytes 
during inflammation.
Macrophages, with important roles in phagocytosis, are known for their increased 
presence in chronic inflammatory settings and tumors. Thereby they produce a range 
of growth factors, cytokines, such as IL-1 ) or
(TNF ), and proteolytic enzymes according to their microenvironment [79]. TNF
sustains tumor and blood vessel growth by stimulating angiogenic factors like VEGF-
A or IL-8, a major angiogenic chemokine [80]. IL-1 enhances tumor invasiveness and 
induces angiogenesis by stimulating TNF and HIF-1 release [80, 81]. Tumor cells 
and macrophages express VEGF-C and -D, thus having an important role in 
lymphangiogenesis [82]. Increased VEGF-C expression is related to lymph node 
metastasis for thyroid, lung or gastro-intestinal cancers [83]. Thus, both blood and 
lymphatic vessel proliferation occur under pathologic conditions, such as 
inflammation or tumor growth. 
Polymorphonuclear leukocytes (PMNs) are known to be involved in the physiological 
progress of menstrual cycle angiogenesis [84]. However, they can also stimulate an
increased release of angiogenic factors within tumors and be the source of these 
factors upon TNF stimulation arising during tumor or chronic inflammation 
progression [85]. In addition, PMNs contribute to inflammatory lymphangiogenesis, 
by increasing VEGF-A bioavailability and secreting VEGF-D [86].
Lymphangiogenesis occurs as a response to inflammatory stimuli with the aim of 
facilitating clearance of antigens, inflammatory cells, and cytokines from inflamed 
sites and of establishing the resolution of inflammation. The sprouting from pre-
existing lymphatics, the characteristic of adult lymphangiogenesis, is mediated by 
VEGF-C and -D signaling upon binding to the main lymphatic endothelial receptor, 
VEGFR-3 [87]. Pro-inflammatory cytokines and bacterial lipopolysaccharide (LPS), 
encountered during inflammation caused by bacterial infections, generate VEGF-C
expression in many cell types [51]. During chronic inflammation, VEGF-A induces 
lymphangiogenesis via VEGFR-2 expressed on lymphatic endothelium. VEGF-A
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mediated lymphangiogenesis is also seen in the draining lymph nodes representing a 
contrast to the angiogenic drive seen during development [88, 89]. Thus, lymph node 
inflammatory lymphangiogenesis can be induced both via VEGF-A/VEGFR-2 and 
VEGF-C and-D/VEGFR-3 signaling [90].
Some chronic inflammatory diseases are actively maintained through 
lymphangiogenesis [91], as demonstrated in chronic airway inflammation [51],
psoriasis [92], ulcerative colitis [93], as well as rejected renal transplants [94].
Experimental blocking of lymphangiogenic factors during inflammation suppresses 
lymhangiogenesis, as well as reactive lymphadenitis, and consequently edema 
persists [51]. A study performed on K14-VEGF-A transgenic mice showed that in 
chronic skin inflammation, blocking VEGFR-2 inhibits angiogenesis and
inflammatory reactions. VEGFR-3 inhibition however prolonged inflammatory 
edema [95]. In a model of transgenic TNF mice with chronic inflammatory arthritis, 
blocking of VEGFR-3 resulted in a decrease of lymph node lymphangiogenesis and 
an augmentation of inflammation [96]. On the other hand, in the same disease setting, 
anti-VEGFR-2 treatment reduced both lymphangiogenesis and the severity of 
inflammation [96]. These findings suggest that induced lymphangiogenesis and
lymphatic drainage are related to the severity of inflammatory lesions and that 
adequate lymphatic drainage may be beneficial during chronic inflammatory 
conditions.
1.3 The tooth biology
The tooth is a highly complex organ comprising organized structures with various 
and specific shapes. It develops within the alveolar bone and after it erupts in the oral 
cavity, the root(s) firmly anchors to surrounding bone. The tooth structure comprises 
of three outer mineralized tissues – coronal enamel, radicular cementum and corono-
radicular dentin which surround the inner non-mineralized soft tissue, the dental pulp. 
21
Figure 4. Schematic representation of the tooth and supporting tissues.
1.3.1 The dental pulp
The dental pulp is a unique tissue confined within rigid walls. It exhibits specialized 
cellular components – the odontoblasts, known for their dentin-deposition activity 
throughout life and upon external aggression - such as caries, and for their 
involvement in sensory transduction [97, 98]. Additionally, the pulp has rich sensory 
innervation [99] and is well supplied with blood vessels [100], which contribute to 
its’ defensive functions. It is also equipped with cellular components necessary for 
antigen recognition and immune reaction, such as T lymphocytes, macrophages and 
the major antigen-presenting cells (APCs), the dendritic cells [101].
Dental caries and traumatic injuries may provide entry-ways for bacteria to the pulpal 
space, hence causing inflammation which may evolve to pulpal necrosis if left 
unattended. It has been shown that teeth with viable dental pulp are more resistant to 
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bacterial invasion of the dentine than teeth with root canal fillings [102], thus the 
important role of the pulp in defense processes.
1.3.2 Pulp vascularization 
Like in other tissues, pulp blood flow brings oxygen and nutrients to the dental pulp, 
while also removing waste products thereafter. The pulp microcirculation is supplied 
by the maxillary artery, which divides into dental arteries and further arterioles that 
enter the teeth. These have a central orientation and give capillary branches towards 
pulp periphery. The blood drains into venules, which are also centrally located. The 
vasculature differs in the crown and root of the tooth. In the root, blood vessels 
penetrate the apical area of the pulp and form tiny branches. Dental crown capillaries
form successive glomerular individualized structures that supply areas of 100-150 μm 
in subodontoblastic and odontoblastic areas [103, 104]. Furthermore, some coronal 
capillaries have been described with a fenestrated structure [105].
An increased blood supply during inflammation leads to angiogenic capillary 
sprouting regulated by hypoxia. Under normal conditions, pro- and anti-angiogenic 
factors and neuropeptides control pulp vascularization [106, 107]. Dentin and pulp 
fibroblasts as well as ECs express pro-angiogenic factors, such as VEGF and 
fibroblast growth factor (FGF-2) [106-108]. Immunohistochemical analysis of normal 
and inflamed pulp has revealed the presence of VEGF under both conditions [109].
Dental pulp stem cells have the capability of differentiation into ECs [110]. This 
indicates that the pulp has the capacities of healing and regeneration processes which 
require angiogenesis.
Even though a lymphatic system is required for fluid and macromolecules transport 
especially during inflammatory conditions, the presence of lymphatics in the dental 
pulp remains controversial. Initial observations suggested that the pulp contains 
lymphatic capillaries [111-113]. This fact was later on disputed, as specific lymphatic 
markers (Prox1) did not reveal any lymphatics in the dental pulp [114]. Berggreen et 
al. [115] found LYVE-1+ immune cells in mouse dental pulp, and VEGFR-3+ vessels 
which were interpreted as lymphatics. And yet, another study partially contradicts 
these findings, as by use of multiple specific lymphatic markers (LYVE-1, D2-
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40/Podoplanin and Prox-1) no lymphatic vessels were identified in human dental pulp 
[116].
1.3.3 The periodontium
The tooth supporting and surrounding structures enclose gingiva, periodontal 
ligament (PDL), cementum and alveolar bone. 
The gingiva is the part of the alveolar mucosa covering the cervical part of the tooth 
and the tooth-carrying portion of the alveolar bone [117].
The PDL contains mainly collagen fibers, anchoring the root surface to the tooth 
socket of the maxilla or mandible, but also various cells – fibroblasts, osteoblasts, 
cementoblasts, progenitor stem cells, epithelial cell rests of Malassez, neural cells, 
and ECs, associated with the vasculature as well as ECM [118-120]. The PDL fulfills 
several functions – tooth support, stability, nutrition and protection, as well as 
mobility and adaptation to mechanical forces. 
Cementum covers the root surface and continues deposition throughout life after 
tooth eruption [121].  There are three types of cementum in human teeth- acellular
afibrillar cementum that covers minor areas of enamel; acellular extrinsic fiber 
cementum located mostly in the cervical and middle root portions, with apical 
exceptions in front teeth; and cellular intrinsic fiber cementum, mostly covering the 
rest of areas, with a predilection for the furcation and apical parts of the roots. 
Sometimes they overgrow each other, resulting in mixed stratified cementum [121, 
122]. It is mainly the cellular intrinsic cementum type which participates in root 
repair processes [121].
Alterations in adult cementum structure and organic as well as inorganic composition 
occur due to pathological changes – bacteria-caused long-lasting inflammation being 
a major example [121, 123, 124]. Even though it is considered that root surface is 
more resistant to resorption than alveolar bone, radicular resorption of cementum and 
dentin does occur upon pulpal pathology, trauma or orthodontic treatment [125, 126].
The key players of this process are odontoclasts, similar cells to osteoclasts 
concerning multinucleated structural and functional characteristics [127].
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The alveolar bone consists of the outer buccal, lingual or palatal cortical plates, and 
the central part containing a large amount of trabecular (spongious) bone with bone 
marrow in between trabeculae. The cortical bone is covered on the external side by 
the periosteum, which contains fibroblasts, osteoclast and osteoblast progenitor cells, 
nerve cells, blood vessels and bone-forming osteoblasts at the innermost part. The 
endosteum covers the inner side of cortical bone and external surface of the 
spongiosa. It also contains osteoblasts, as well as flat, bone-lining cells with no active 
bone secretory function [128, 129]. Other cells of the bone are the osteocytes which 
participate in bone remodeling processes along with osteoblasts and osteoclasts and 
actively maintain the bone matrix [130, 131]. Osteoclasts, multinucleated giant cells,
are present on bone surfaces or intracortically and are responsible for bone resorptive 
activity [132].
1.3.4 Blood supply of the periodontium
The periodontium is highly vascularized. Alveolar arteries supply the PDL with three 
different branches: the dental, the interradicular and the interdental. Before entering 
the tooth apex, the dental artery emerges from the bone and gives off afferent 
subdivisions that form a vascular network in the apical third of the PDL [128]. While 
the interdental and interradicular arteries give mostly lateral branches, all these 
vessels within the PDL intercommunicate [128]. The apical and coronal thirds of the 
PDL are generally more vascularized than the middle third. Arteries are commonly 
accompanied by larger venous channels. Lymphatics exist in the gingiva, where they 
start as blind-ended vessels and pass along the external surface of the alveolar bone 
[133]. Gingival lymphangiogenesis occurs during periodontal disease development 
[134] and a recent study has shown the protective role of lymphatics in periodontal 
inflammation [135]. While no lymphatic vessels were detected at the border between
gingiva and PDL [133], some LYVE-1+ vessels have been described to transverse 
interdental bone [115]. The lymphatic drainage of the PDL is still debated [136].
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1.4 Bone remodeling 
Bone is a dynamic tissue with constant forming and resorption activity in order to 
maintain mineral homeostasis and structural integrity [137]. During the so-called 
coupling sequence, osteoclasts resorb the mineralized matrix, while osteoblasts form 
new bone matrix [138]. This process is regulated by local and systemic elements, 
such as mechanical load, calcium levels, paracrine and endocrine factors. 
Figure 5. Schematic illustration of bone remodeling cycle. Micro-cracks lead to 
osteocyte apoptosis which determines osteoclast precursors’ recruitment. M-CSF and
receptor activator of nuclear factor kappa-B ligand (RANKL) are produced by bone-
lining cells and activate osteoclasts. Bone morphogenic proteins (BMP), 
transforming growth factor- (TGF- ), insulin growth factor-1 (IGF-1), 
cardiotrophin-1 (CT-1) are osteoclast-derived molecules which control bone 
apposition by osteoblasts. Newly-formed osteocytes secrete sclerostin, which 
terminates the bone secretion. (Shapes modified from Servier Medical Art, 
Laboratoires Servier, Suresnes, FR).
The activation of resorption occurs via apoptosis of osteocytes around a micro-
fracture [137]. This leads to osteoclast precursor recruitment, osteoclastogenesis and
bone resorption. The osteoclasts then die by apoptosis, which recruits osteoblast 
precursors. The resorbed area is filled with bone formed by osteoblasts, concluding 
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the cycle [137]. Alterations of this process can disturb the balance with pathological 
consequences [138].
Bone remodeling is controlled by signals between bone cells [139, 140], but also via 
sympathetic nervous system, hematopoietic stem cells, inflammation and the immune 
system, and vasculature [141-143]. In the 1990’s the RANKL/RANK/osteoprotegerin 
(OPG) system was discovered and made it possible to understand more of the 
mechanism of bone resorption and remodeling [144, 145]. RANKL, the major 
osteoclast differentiation factor, is expressed by osteoblasts upon stimulation by a 
multitude of factors, but also by activated T cells, an indication of the immune system 
influencing bone resorption [146]. Under homeostatic conditions, RANKL binds to 
RANK, the receptor on osteoclast surface, thus activating the NF-kB pathway and 
resulting in bone resorption. Expression of RANKL can be regulated by 
glucocorticoids, Vitamin D3, IL-1, TNF or LPS [147-150]. The RANKL/RANK 
binding is inhibited by OPG, a decoy receptor of the osteoblasts for RANKL, thus 
limiting bone resorption [144]. Under pathologic conditions, such as rheumatoid 
arthritis, periodontal disease, osteoporosis, metastatic bone tumors or multiple 
myeloma, the ratio RANKL/OPG increases in favor of bone breakdown [151].
1.5 Dental inflammation
As a response to injuries, living tissues respond with inflammation. The causes 
include microbial infections, trauma, chemical injuries, tissue necrosis and 
hypersensitivity reactions. Dental inflammation caused by microorganisms has been 
well established [152-154].
Gingival inflammation, a common disease with high prevalence, is caused by 
microorganisms; it can be reversed through treatment, but can also evolve to chronic 
periodontal breakdown. Dental caries is the most prevalent infectious disease, 
affecting most individuals, with both functional and economic impacts [155]. These 
lesions, along with tooth fractures or iatrogenic maneuvers are the portal of bacteria
to the dental pulp, causing pulpal inflammation. If untreated, pulpitis evolves to pulp 
necrosis and apical periodontitis, with destructive processes of the bone.  The human 
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oral cavity is host to approximately 700 bacterial species [156, 157]. It is mostly 
anaerobic gram-negative bacteria and their virulence factors that take part in dental 
disease development [158, 159].
The inflammatory response consists of a vascular and a cellular component. 
Vasodilation and increased blood flow at sites of inflammation go along with 
increased vascular permeability, resulting in plasma and protein extravasation into 
injury site and movement of leukocytes from vessels into the inflamed tissue [160].
The initial recognition of bacteria and their by-products is mediated by tissue-resident 
macrophages, mast cells, fibroblasts or dendritic cells via their toll-like (TLRs) and 
nucleotide binding oligomerization domain receptors (NODs) [161, 162]. In turn, this 
activation of the innate immune response leads to production of a variety of 
inflammatory mediators, including chemokines and cytokines. The vasodilation and 
extravasation of neutrophils represent the immediate effects of these mediators. When 
reaching the affected site, activated PMNs try to eliminate pathogens by releasing 
toxic contents of their granules [163]. If successful, resolution of inflammation 
occurs. If not resolved, a chronic inflammation takes place, where the PMN infiltrate 
is replaced with macrophages, B- and T- lymphocytes – characteristic of the adaptive 
immune response. Macrophages usually predominate in chronic inflammation, being 
responsible for the release of multiple cytokines and inflammatory mediators with 
both pro- and anti-inflammatory roles, thus also affecting resident tissue. Along with 
dendritic cells, they present antigens via their major histocompatibility complex 
(MHC) class II to T-helper (Th) cells in the regional lymph nodes, activating these 
cells. This leads to production of more cytokines that contribute to increased 
macrophage activation and to formation of memory B- and Th-cells. Furthermore, B 
lymphocytes also become activated, developing into antibody-producing plasma cells 
against the presented antigens. Thus, lymph node enlargement seen during 
inflammation, the lymphadenitis, is the result of immune cell reactions which try to 
prevent the spread of a local aggressor throughout the organism.
Little is known on lymphangiogenesis and lymphadenitis occurring during dental 
inflammation. Lymphangiogenesis in the gingiva during periodontal disease has
previously been described [134]. Clinical findings have shown that during acute 
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phases of marginal and apical periodontitis mainly caused by bacteria, local and 
regional lymphadenitis arise [164]. Within the dental pulp, the presence of lymphatics 
is still disputed. A study on normal and inflamed pulps suggests that during 
inflammation, lymphangiogenesis occurs as more CD31+/VEGFR-3+ vessels have 
been seen [165]. Knowing that VEGFR-3 is also expressed on some fenestrated blood
vessels and that no other lymphatic markers have been employed in that study, this 
evidence [165] remains controversial. An interesting recent finding shows the 
migration of pulpal dendritic cells to regional lymph nodes as soon as 16 hours upon 
cusp trimming and bacterial exposure. This may lead to further immune cell 
recruitment [166]. The exact migratory pathways of pulp APCs to regional lymph 
nodes are in need of further investigation.
1.5.1 Apical periodontitis
The periapical lesion is in fact the result of the host’s immune response upon constant 
bacterial aggression from the root canal aiming at confining the infection to the 
endodontic space. Apical bone loss in the forms of granulomas or cysts, which dental 
practitioners notice on radiographs as radiolucent areas, represents a main indicator of 
periapical disease (Figure 6).
Figure 6. Radiographic exemplifications of teeth with deep, untreated or secondary 
caries and periapical lesions (unpublished images, Department of Endodontics,
University of Bergen).
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A necrotic dental pulp lacks blood supply and subsequently inflammatory cells that 
would eliminate bacteria [167]. Thus, bacteria penetrating the root canal towards the 
apex trigger a periapical immune defense with a rich cellular component consisting of 
PMNs, macrophages, B- and T-lymphocytes or plasma cells [168-171]. Fibroblasts, 
osteoblasts, osteoclasts, eosinophils, mast cells and epithelial cells are also among 
cells found in periapical lesions [172, 173]. Figure 7 exemplifies cellular infiltrates in 
mouse (A and B) and human (C) periapical lesions, as well as presence of osteoclasts
(D) in a human apical periodontitis lesion.
Figure 7. A and B. Periapical lesions induced in mice, following 21 days of pulpal 
exposure, (H&E staining). Necrotic pulp (NP) remnants are visible in the root 
canals. Periradicular cellular infiltrates of different intensities (arrowhead), along 
with areas of bone resorption (arrows) are observed. C. H&E staining of human 
periapical lesions revealing different cellular and fibrous infiltrates. D. TRAP 
staining of human periapical lesion exemplifying pre-osteoclasts or osteoclasts 
(arrows, intense red staining) in the body of human periapical lesion (Unpublished 
data).
The inflammatory response cannot occur without its’ vascular component. The 
extravasation of PMNs, of high importance in periradicular disease development, 
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follows vascular hyperemia, congestion and local edema [172]. Though mostly 
protective, PMNs also degrade host tissues, not just microorganisms, due to release of 
their cytotoxic granules, especially in the acute phases of apical periodontitis where 
they predominate [172].
Reports vary considering the dominating type of cells in established periapical lesions 
with either macrophages [170, 174] or lymphocytes [175, 176] taking the lead. 
Macrophages have central roles in innate, as well as acquired immunity [177]. In rat 
models of apical periodontitis, it has been shown that their numbers increase in the 
first 10 days of lesion development, maintaining similar levels for up to 60 days and 
decreasing thereafter [178]. Through their phagocytic role, they prevent 
dissemination of bacteria from the root canal to the surrounding bone. By being 
APCs, they process the antigen, present it to Th cells, which they also activate, thus 
triggering the adaptive immune response. Along with IL-1 and TGF- production,
macrophages also release metallo-proteases (elastase, collagenase) and 
prostaglandins, which participate in the bone destructive process [177].
Usually T cells are more numerous than B cells [175]. Of the T-cells, Th1, Th2 and 
Th17 as well as T-cytotoxic (Tc) subtypes were identified in periapical lesions [171, 
179]. Th1 cells produce IL-2 and IFN ), which control cell-mediated 
immunity, while Th2 cells secrete IL-4, -5, -6, -9, -10 and -13 that regulate plasma 
cells and humoral immune response [180-182]. Out of these cytokines, IL-6 and IL-
10 may exert anti-inflammatory effects in bone inflammation [183, 184].  Th17 cells 
are known for IL-17 production, a cytokine, which so far has been described with 
both pro- and anti-inflammatory functions [179, 185]. They also release IFN , with 
protective effects in periapical inflammation [186]. Upon cytokine activation, B-cells
proliferate into plasma cells, which produce antibodies to bacterial antigens [187]. An
overview of periapical cellular interactions during apical periodontitis development is 
given in figure 8.
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Figure 8. Schematic representation of major cellular interactions during periapical 
disease development. Bacteria and their products from the root canal are attacked by 
extravasated PMNs from blood vessels. Macrophages (MØ) recognize antigens via 
TLRs, engulf these and present the information to T cells, activating the adaptive 
immune response. Activated macrophages enhance migration of monocytes and 
PMNs from vessels in the area via IL-1. B-cells activation determines antibody 
production (IgG) against specific antigens. Many mediators are being produced, 
some with osteoclastic stimulating effect (Granulocyte macrophage colony-
stimulating factor (GM-CSF), TNF , IL-1), others with anti-inflammatory roles (IL-6, 
IL-10). Osteoclasts (Oc) are also activated due to release of RANKL and Granulocyte 
colony-stimulating factor (G-CSF) by osteoblasts (Ob) in the periapical bone (Shapes 
modified from Servier Medical Art, Laboratoires Servier, Suresnes, FR).
The interplay between ECs, PMNs, macrophages, lymphocytes and osteoclasts 
characterize these endodontic lesions, along with the main consequence of this 
process – bone resorption [167, 172, 188]. Osteoclastic bone breakdown is stimulated 
through the induction of the major pro-inflammatory cytokines such as IL-1 , IL-1 ,
32
RANKL or TNF [189, 190]. IL-1 and IL-1 are produced in apical periodontitis 
lesions by several types of cells – macrophages, PMNs, fibroblasts and osteoclasts 
[191, 192]. The role of IL-1 in apical periodontitis development was demonstrated by 
inhibiting IL-1 receptor and showing a 60% reduction of bone destruction [187].
Additional to bone resorption enhancement, IL-1 can stimulate T- and B-cells [193],
enhance leukocyte adhesion to endothelial walls or activate the production of 
prostaglandins and proteolytic enzymes [172].
Fibroblasts, macrophages and PMNs are also the source of TNF , which mediates 
RANKL stimulation of osteoclast differentiation through autocrine mechanism [194],
hence stimulating bone resorption. 
Although osteoblasts are the main source of RANKL, B- and T-cells [195] as well as  
fibroblasts [196] also express this factor. Furthermore, it has been suggested that 
other cells, like macrophages, PMNs, ECs and epithelial cells express RANKL in 
periapical lesions [197].
                            
Figure 9. Scattered cells (arrows) in a human periapical lesion stained positive for 
RANKL (Unpublished data).
Microorganisms, inflammatory molecules such as IL-1, TNF and IFN or even 
chemokines themselves stimulate the production of chemokines at sites of apical 
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periodontitis [198]. Osteoclast differentiation and activation is also induced by 
chemokines, such as IL-8/CXCL8 [199], macrophage inflammatory protein- (MIP-
1 )/CCL3 or regulated on activation, normal T cell expressed and secreted 
(RANTES)/CCL5 [200, 201]. Monocyte chemotactic protein (MCP-1)/CCL2, 
abundantly produced in chronic inflammation, is associated with osteoclast 
chemotaxis and differentiation [202, 203], while mediating monocyte recruitment to 
bone inflammatory sites and being involved in bone remodeling [204, 205]. Dentin 
proteins stimulate PMN migration by inducing the release of keratinocyte 
chemoattractant (KC)/CXCL1 and MIP-2/CXCL2 [206]. In granulomas, RANTES is 
associated with recruitment of CD4+ Th cells and CD68+ macrophages, whereas MIP-
1 and MIP-1 /CCL4 are related to the CD8+ Tc population. Moreover, the increased 
expression of RANTES and MCP-1, in cysts versus granulomas is indicative of 
augmented osteoclast recruitment and thus may be of importance in periapical disease 
development [207].
Cytokines and chemokines are also important mediators of angiogenesis. IL-1 and 
TNF are known inducers of angiogenic responses [80, 81], while IL-6 has also been 
shown to promote VEGF-dependent angiogenesis in tumor settings [208]. MCP-1 can 
trigger EC migration and vessel sprouting [209], whereas mice lacking MCP-1 have 
experienced delayed wound healing, indicative of the angiogenic involvement of this 
chemokine [210].  Apart from its’ role in osteoclastogenesis, IL-8 is also a potent 
angiogenic factor [211], acknowledged for intensifying the local vascular response in 
apical periodontitis [172].
Additional to angiogenic cytokines and chemokines, recent studies have
demonstrated the presence of the angiogenic factors FGF-2 and VEGF in these 
lesions [212, 213]. Microvessel density counts have revealed increased amounts of 
blood vessels in periapical lesions with intense inflammatory infiltrates [214]. During 
periods of exacerbation of chronic periapical inflammation, vasodilation and 
increased vascular leakage can occur, seen as regional mucosal swelling. This process 
is often accompanied by local lymphadenitis. The lymphangiogenesis mechanism in
the draining lymph nodes during acute and chronic apical periodontitis is still in need 
of further investigations.
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All of the above indicate the complex development of periapical disease, with 
intricate vascular and cellular processes taking place.
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2. Aims of this study
The dental pulp is a well vascularized tissue, very often under inflammatory insults. 
Pulpal inflammation, when untreated, further evolves to necrosis of the tissue and 
periapical inflammation. The general aims of this study were to identify and map the 
presence of the VEGF family and receptors in normal dental pulp, as well as in apical 
periodontitis and to establish their roles in periapical disease development.
Specific aims
To determine the existence and localization of VEGFs and VEGFRs during 
development of apical periodontitis in a rat model (Paper I).
To investigate the presence of VEGFs and VEGFRs in human dental tissue 
with focus on normal dental pulp and periapical lesions (Papers II and III). 
To examine VEGF signaling at the gene level in normal dental pulp versus 
normal PDL (Paper III).
To investigate the existence of lymphatics in periapical tissues and human 
pulp (Papers I-III).
To study the roles of VEGFR-2 and -3 signaling during development of apical 
periodontitis in a murine model by individual or combined blocking of these 
receptors (Paper IV).
To investigate inflammatory reactions in regional draining lymph nodes with 
respect to lymph node size and lymphangiogenesis upon pulpal exposure and 
systemic inhibition of VEGFR-2 and/or -3 (Paper IV).
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3. Materials and methods
Animal experiments (Papers I and IV)
Female Wistar rats (Paper I) and male C57BL/6 mice (Paper IV) were used. The
animals were housed in polycarbonate cages at the animal facility at least one week 
prior to experiments. They were fed standard pellet diet and given water ad libitum.
The experiments were approved by the Regional Committee for Animal Research 
Ethics, University of Bergen, under the supervision of the Norwegian Experimental 
Animal Board. 
Anesthesia: The rats were anesthetized with intramuscular injections of 
medetomidine/Domitor® (Orion Pharma, Espoo, FI), 0,4 mg/kg body weight and 
Ketamine/Ketalar® (Pfizer, Solentuna, SWE), 60 mg/kg body weight (Paper I). The 
mice were anesthetized  with ketamine/Ketalar® 100 mg/kg body weight and 
Xylazine/Rompun Vet® (Bayer, Leverkusen, DE) 10 mg/kg body weight (Paper IV).
Pulp exposure (Paper I): First right maxillary and mandibular molars were drilled 
with a round bur until the pulp was exposed. Thereafter they were left open to the 
oral environment for either 10 days or 3 weeks for periapical lesions development.
Figure 10. Picture taken during pulp exposures induced in mice. The anesthetized 
animals were placed on a jaw retraction board. Instrumentation of root canals in first 
mandibular molars was done upon pulp exposure with a 0.6 K-file. 
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Pulp exposure (Paper IV): Bilateral first mandibular molar pulps were exposed and 
removed with round burs. The mesial and distal canals were filed with a 0.06 K-file. 
The teeth were left open to the oral cavity for either 10 days or 3 weeks during which 
periapical lesions were developed.
Systemic treatments (Paper IV): Administration dosage and frequency of each 
substance are presented in the manuscript. Briefly, upon pulp exposures, the mice of 
both observation groups were injected intraperitoneal throughout the experimental 
periods with either normal IgG (controls), anti-VEGFR-2 (anti-R2), anti-VEGFR-3
(anti-R3) or combined anti-VEGFR-2 and-3 (anti-R2/R3) antibodies. 
Upon experiment completion and euthanasia of all animals with anesthesia overdose, 
rats and mice jaws (Papers I and IV) and mice lymph nodes (Paper IV) were collected 
for further analysis.
Human tissue collection (Papers II and III)
Periapical lesions were collected after endodontic surgery of teeth diagnosed with 
chronic apical periodontitis (Paper II). Normal PDL (Papers II and III) and dental 
pulps (Paper III) were extracted from surgically removed healthy wisdom teeth. All 
human tissue was provided by the Department of Maxillofacial Surgery, Haukeland 
University Hospital, Bergen, upon patient written consent. The samples were stored 
in an authorized bio bank (REK 3.2008.1750) at -
RNA extraction  and quantitative real-time PCR analysis 
(Papers I-III)
Rat jaws were freed of gingival remnants and bone blocks containing the first molar 
with the periapical lesion were dissected. The dissected tissue (Paper I), human 
granulomas (Paper II), normal PDL (Paper II and III) and dental pulp (Paper III) were 
placed in RNAlater® (Ambion, Austin, TX, USA) and frozen until further handling. 
Total RNA was extracted using commercially available RNAeasy minikit (Qiagen, 
Chatsworth, CA, USA) following manufacturer’s protocol. Upon homogenization 
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and an on-column DNase digestion with RNase-free DNase set (Qiagen), quality was 
assessed by gel electrophoresis to ensure that 28S and 18S ribosomal RNA were 
clearly evident.  A spectrophotometer (Nanodrop, Wilmigton, DE) was used for RNA 
quantity measurements. First strand cDNA synthesis was performed with M-MLV 
Reverse Transcriptase (Ambion) and Random Hexamer Primer (Fermentas GmbH, St 
Leon-Rot, DE) with 2 μg total RNA for rat samples (Paper I) and RT2 First Strand 
Kit (Qiagen) using 1 μg RNA for human tissue samples (Papers II and III). 
Gene expression analysis of rat periapical lesions was performed by use of 
predesigned TaqMan gene expression assays (Applied Biosystems, Foster City, CA, 
USA) for VEGF-A, -C and VEGFR-3 with ACTB as a control gene (Paper I). Human 
samples (Papers II and III) were screened for 84 genes contained in the Human 
VEGF Signaling RT2 Profiler PCR Array System (Qiagen). Both human pulp and 
periapical lesion samples were normalized to calibrator PDL and 5 genes served as 
references (GAPDH, B2M, ACTB, HPRT1, RPL13A).  An RT-PCR thermocycler 
(LightCycler 480, Roche Diagnostics AG, Rotkreuz, SUI) was used for all analyses. 
Expression profiles of the target genes were measured relative to the mean critical 
threshold (Ct) of the reference genes by using the Ct method described by Livak 
and Schmittgen [215].
Histology (Papers I, II and IV)
Representative rat jaws (Paper I) and periapical lesions (Paper II) were embedded in 
paraffin, sectioned (5 m) and stained with H&E. Cryosections (12-14μm) from 
exposed and control mice lymph nodes (Paper IV) were also stained with H&E.
Immunohistochemistry (Papers I-IV)
Rats deeply anesthetized with sodium pentobarbital (Mebumal) were transcardially 
perfused with heparinized saline, followed by 4% PFA with 0,2% picric acid in 0.1M 
phosphate-buffered saline, pH 7,4 (Paper I). The jaws were removed and decalcified 
in 10% EDTA, saturated in 30% sucrose and stored at -80° until cryosectioning (20 
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m). In paper IV, mice mandibles were removed without prefixation. Hemi-
mandibles exposed for 10 days were decalcified in 10 % EDTA and post-fixed with 
4% PFA upon cryosectioning during staining protocols. Mice hemi-mandibles 
exposed for 21 days were fixed with 4% PFA, stored in 50% ethanol, used for CT 
analysis and thereafter followed the same treatment for immunohistochemical (IHC) 
analysis. Lymph node cryosections were PFA fixed prior to staining.
In papers II and III, frozen human periapical lesions and dental pulps were 
cryosectioned (12-16μm) and stored at -80° until further handling. They were used 
either for single staining with the avidin-biotin peroxidase (ABC) method and nickel-
enhanced 3, 3’-diaminobenzidine (DAB) as the chromogen (Papers I-IV) or for 
immunofluorescent procedures (Papers I-IV). In papers I-III the staining aimed at 
identifying the presence and localization of VEGFs and their receptors in periapical 
lesions and dental pulp. In paper IV, IHC was used for identification and 
quantification of immune cells (neutrophils and macrophages) and blood vessels in 
induced apical periodontitis, as well as lymphangiogenesis occurring in draining 
lymph nodes. Details on the used primary and secondary antibodies, as well as 
protocols are given in papers I-IV.
The specificity of all immune reactions was tested by omission of the primary 
antibodies and/or substitution with isotype controls. Sections were visualized in a 
photomicroscope (Nikon Eclipse E600; Nikon Instruments, Kanagawa, Japan) or a 
fluorescent microscope (Axio Imager; Carl Zeiss Microimaging Inc, Jena, Germany) 
connected to AxioCam Mrm camera (Carl Zeiss) that used the AxioVision 4.8.1 (Carl 
Zeiss) imaging system. 
TRAP staining (Paper IV)
In order to identify and quantify osteoclasts, sections from exposed mice jaws were 
stained with tartrate resistant acid phosphatase (TRAP) according to manufacturer’s 
(Sigma-Aldrich, USA) instructions.
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Quantification of osteoclasts, neutrophils, macrophages and 
blood vessels (Paper IV)
Immunolabeled cells (TRAP+ osteoclasts, Ly-6.B2+ neutrophils, F4/80+
macrophages) and CD31+ vessels were counted in the periapical lesions from the 
apical constriction to the bone periphery on 2-4 sections from each mouse under a 
photomicroscope, quantified with Lucia imaging software (Lucia, v. 480; Laboratory 
Lymph nodes analysis (Paper IV)
Lymph node cryosections from the 21 days exposed mice and untreated animals 
(negative controls) were subjected to histological (H&E staining) and LYVE-1
immunofluorescent analyses. Histological evaluations were used for total area 
measurements (mm2), while LYVE-1+ sinus areas were measured in the hilum and 
medulla in 4-6 sections from each mouse in a 350 mx350 m grid. All evaluations 
were done with Lucia imaging software upon image capture in either a 




PFA fixed hemi-mandibles from each group exposed for 21 days were washed with 
phosphate buffer, stored in 50% ethanol, number coded for blinded analysis and sent 
for μCT evaluation to the Forsyth Institute, Boston, MA, USA. The analysis was 
performed by means of a compact fan-beam-type tomograph (μCT40, Scanco 
Medical, Basserdorf, SUI). The data were exported into DICOM format, re-sliced in a 
standardized manner using the ImageJ software (Wayne Rasband, National Institutes 
of Health, Bethesda, MD, USA) to obtain pivotal sections containing the entire length 
of the root canals and periapical lesions.
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Lesion size measurement (Paper IV)
Periapical lesion sizes (mm2) of the distal roots were measured on 2-4 sections from 
each mouse in mesio-distal (both observation times) and bucco-lingual (after 21 days 
only) directions on cross-sectional areas containing root canal and lesions, using 
Adobe Photoshop CS4 (Adobe Systems, San Jose, CA, USA) and Lucia imaging 
software. A standardized device was placed through the apical constriction and the 
lesions were outlined to the bone periphery. All technical details are given in paper 
IV.
Protein extraction (Paper IV)
Dissected bone blocks containing periapical lesions developed after 21 days, and also 
from negative controls were homogenized in 400μL cell lysis buffer mix, the 
supernatants collected and stored at -
Multiplex and ELISA analysis (Paper IV)
A 96-well Milliplex MAP mouse cytokine/chemokine magnetic bead panel 
(MCYTOMAG-70K, Millipore, MA, USA) was used for the simultaneous detection 
of 25 cytokines in mouse bone blocks containing periapical lesions. G-CSF, GM-
CSF, IFN , IL-1 , IL-1 , IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL-
12(p70), IL-13, IL-15, IL-17, IP-10, MKC, MCP-1, MIP-1 , MIP-1 , MIP-2, 
RANTES and  TNF were the analyzed cytokines according to manufacturer’s 
instructions. A range of 3.2-10.000 pg/ml recombinant cytokines was used to 
establish the standard curves. The levels of inflammatory molecules were measured 
using the multiplex array reader from Luminex™ Instrumentation System (Bio-Plex 
Workstation from Bio-Rad Laboratories, Hercules, CA, USA) and concentrations 
were calculated with software provided by the manufacturer (Bio-Plex Manager
Software). The RANKL concentration in the same samples was measured with a 
Quantikine Enzyme Linked Immunosorbent Assay (ELISA) kit (R&D Systems, 
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Minneapolis, MN, USA), presented with a 96-well plate, following manufacturers’ 
protocol. The concentrations were calculated and presented as pg/mg tissue –
corresponding to samples’ weights.
Statistical analyses (Papers I-IV)
In papers I-III, qRT-PCR results were statistically analyzed. The p values were 
calculated based on an unpaired Student’s t-test comparing the replicate 2- values 
for each gene. 
In paper IV, all data was subjected to statistical analysis and the following tests were 
employed: One-way ANOVA and Bonferroni post-hoc test for normally distributed 
populations; Kruskal-Wallis and Dunn’s post-hoc test for non-normally distributed 
populations; Two-way ANOVA and Bonferroni post-hoc test for grouped analysis. 
A p value of <0.05 was considered statistically significant.
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4. Summary of results
4.1 Expression of VEGFs and their receptors in rat apical 
periodontitis (Paper I)
Immunohistochemical analysis demonstrated that VEGF-A, -C, -D and VEGFR-2
and -3 were expressed on cells and vessels in non-exposed control teeth PDL. Some 
PDL cells with fibroblastic appearance and others lining the bone or the root surface 
were positive for VEGFR-2 and -3.
All the investigated factors and receptors showed more intense staining on cells and 
vessels in induced periapical lesions at both 10 days and 3 weeks exposure times. 
With increased exposure time, the degrees of pulpal necrosis, periapical inflammatory 
infiltrate, root- and bone resorption were also amplified.
Within the infiltrates, CD68+ macrophages and HIS48+ neutrophils were sources of 
investigated VEGFs. Multinucleated CD68+ cells lining the bone, indicative of 
osteoclasts, were also positive for VEGFR-2 and-3.
At gene level, a significant up-regulation of VEGF-A and VEGFR-3 was observed 
after induction of periapical lesions.
4.2 Presence of VEGFs and VEGFRs in human dental 
tissues (Papers II and III)
Periapical lesions: All lesions presented with heterogeneous morphologies. VEGF-A,
-C, -D and VEGFR-2 and -3 were found on vWF+ blood vessels, ELA-2+ neutrophils, 
CD19+ B- and CD3+ T-lymphocytes, as well as CD68+ macrophages.
Normal dental pulp: CD68+ macrophages and CD3+ T-cells were the major cellular 
sources of VEGF-A, -B, -C, -D and VEGFR-2 and -3. CD31+ blood vessels were 
positive for the same VEGFs and their receptors with the exception of VEGF-B. No 
ELA-2+ neutrophils or CD19+ B lymphocytes could be identified in the analyzed 
normal dental pulp.
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Gene expression analysis: Analysis with the Human VEGF Signalling RT² Profiler™ 
PCR Array System revealed that out of 84 investigated genes, 27 and 67 were more 
than 2-fold altered in periapical lesions and dental pulp respectively, compared to 
control PDL. VEGF-A, -D and VEGFR-3 showed a non-significant up-regulation in 
periapical lesions. A significantly increased expression of VEGFR-3 was seen in 
dental pulp samples, while VEGFR-1, -2 and VEGF-D were non-significantly 
amplified in the same tissue.
4.3 Existence of lymphatics in dental pulp and periapical 
tissues (Papers I-III)
No lymphatic vessels could be identified in human dental pulp, while double 
immunofluorescent staining revealed the presence of LYVE-1+/CD68+ cells with 
dendritic appearance. No LYVE-1+ vessels could be localized in rat or human 
periapical lesions, indicative of all vessels being of angiogenic origin in both species.
Some CD68+ macrophages were also positive for LYVE-1 in the investigated human 
periapical lesions. 
4.4 The effects of VEGFR-2 and -3 signaling during 
development of murine apical periodontitis (Paper IV)
Lesion sizes: Systemic inhibition of either VEGFR-2 or -3 resulted in a fast lesion 
size development until day 10. Thereafter, a slowed progression was recorded. 
Combined inhibition of VEGFR-2 and -3 or IgG-treated controls showed slower 
growth of lesions until day 10, but all four groups reached similar levels on day 21.
Immune cells, blood vessels and osteoclasts: Blocking of VEGFR-2 significantly
increased Ly-6.B2+ neutrophils, along with TRAP+ osteoclasts upon 10 days of 
exposure compared with the other test groups (p<0.05). After 21 days, neutrophil 
infiltrates were substantially increased upon either VEGFR-2 or VEGFR-3 blocking. 
Anti-R2/R3 treatment resulted in fewer F4/80+ macrophages and TRAP+ osteoclasts 
on day 10. The latter systemic treatment also reduced angiogenesis seen on both 
observation times as fewer CD31+ blood vessels within the lesions.
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Cytokine expression: In addition to RANKL, 17 out of 25 cytokines and chemokines 
were expressed in periapical lesions. The pro-inflammatory cytokines IL-1 ,
RANTES, TNF , IL-17 and MCP-1 showed the highest values upon VEGFR-2
inhibition and the lowest expression in the anti-R2/R3 group. A tendency to down-
regulation of many cytokines (RANKL, IL-1 , IL-6, IL-17, MCP-1, MIP-1 , MIP-
1 , MIP-2, RANTES and TNF ) was observed in the anti-R2/R3 group, statistically 
significant for MCP-1 and RANKL compared to the IgG group (p<0.05).
Lymphadenitis and lymphangiogenesis in regional lymph nodes: Significantly bigger 
lymph nodes were found upon anti-R2 compared with anti-R2/R3 treatment and 
controls. The LYVE-1+ area fraction in the lymph nodes hilum and medulla, 
indicative for lymphangiogenesis, was greater in the IgG treated group compared to 
the other groups, yet only significant in the medulla (p<0.05).
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5. General discussion
The processes of angio- and lymphangiogenesis, mediated through the VEGF family 
are of high importance in physiological processes, such as growth or wound healing, 
but also in major pathological settings of tumor progression, inflammation and bone 
resorption.
VEGF-A has been previously found in normal dental pulp where bacteria can up-
regulate its’ expression [216, 217]. The main angiogenic receptor, VEGFR-2, has 
been described in primary and permanent dentition pulps [218]. The presence of 
VEGFR-3+ vessels in mouse and human dental pulp has been reported [115]. An
association between the presence of VEGF-A and the development of apical 
periodontitis has also been made [212, 214, 219].
However, other members of the VEGF family had not yet been addressed in the 
context of location and signaling patterns in periapical disease or dental pulp. 
The focus of this thesis was to investigate the presence of VEGF family and their 
receptors in periapical lesions and in normal dental pulp. The existence of lymphatics 
was also evaluated in these tissues. The implication of VEGFR-2 and/or -3 signaling 
in murine periapical disease development was studied with respect to lesion size, 
local inflammatory and vascular reactions as well as regional lymphangiogenic 
responses of the lymph nodes.
5.1 Presence of VEGFs and VEGFRs in apical 
periodontitis (Papers I and II)
By using an animal model of apical periodontitis, the disease development can be 
tracked from its acute phase (until day 7), through an active phase between days 7 
and 20 and slowing down thereafter as it enters a chronic stage [187]. Human 
samples of periapical lesions, even though essential for providing further information, 
give no data on the time aspect of disease progression, nor on the surrounding 
structures that are known to be affected by the infection, like dentin, cementum and 
bone.
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In the rat experimental model, immunohistochemical analysis revealed the presence 
of VEGF-A, -C, -D and VEGFR-2 and -3 on cells and vessels in both normal PDL 
and bone and in inflamed areas. Inflammation led to increased staining of the 
analyzed factors and receptors over the entire observation period. The involvement of 
immune cells in triggering periodontal and periapical bone resorption is well known 
[188]. We therefore sought at identifying the cells expressing VEGFs and VEGFRs, 
thus also finding their possible involvement in periapical inflammation.
CD68+ macrophages and HIS48+ PMNs expressed the investigated factors and 
receptors. Double immunofluorescent staining of B- and T- cells in human periapical 
lesions added these cells to the VEGFs and VEGFRs sources. Taken together, these 
findings indicate that immune cells produce VEGFs and VEGFRs which are involved 
in periapical disease development and that these cells may communicate with each
other and with ECs.
Interestingly, our results showed the expression of all investigated VEGFs and 
VEGFRs only on vessels of angiogenic origin, thus contradicting the presence of 
lymphatics in the apical periodontium. Former studies have revealed the presence of 
VEGFR-3 on lymphatic ECs, but also on fenestrated blood capillaries, blood vessels 
in inflammatory tissues, macrophages and dendritic cells [44, 46, 220]. Our results 
find VEGFR-3 positive blood vessels in rat normal and inflamed areas of PDL and 
periapical bone and also in inflamed human periapical lesions. We confirm earlier 
data that identified macrophages as the source of LYVE-1 in a pathologic context 
[221, 222]. However, in our investigated tissues, these cells couldn’t be related to 
growth of lymphatic vessels. Their role requires further investigation.
Another novel finding was the presence of CD68+ multinucleated cells, indicative of 
osteoclasts, in the periphery of rat periapical lesions, cells which also expressed both 
VEGFR-2 and -3. The role of osteoclasts in periradicular diseases remains 
undisputed. In vitro studies have shown that VEGF-A enhances osteoclastic bone 
resorption via VEGFR-2 [223] and that the interaction between VEGF-C, -D and 
RANKL mediates osteoclast differentiation [224]. Due to their binding affinities to 
both VEGFR-2 and -3 we can hereby assume that VEGF-C and -D are involved in 
osteoclast regulation in vivo.
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At the gene level, the up-regulation of VEGFR-3 and VEGF-A upon rat pulp exposure 
was significant at both observation times. These genes, along with VEGF-D were 
non-significantly up-regulated in human periapical lesions compared with control 
PDL. PKC, a gene related to increased endothelial activity, PI3K, involved in EC
migration and survival and PLA2G6, which induces pathologic VEGF-A
angiogenesis, were all significantly up-regulated in the analyzed periapical lesions. In 
contrast, SHC2, which participates in VEGF-induced signaling by influencing 
VEGFR-2 activation, was found significantly down-regulated. Accordingly, VEGFR-
2 was also down-regulated. In another rat study where apical periodontitis was 
induced and CD31+ BECs were isolated, the gene expression of VEGFR-2 decreased 
after day 14 of pulp exposure [225]. We can therefore assume that in human chronic 
apical periodontitis, where time of lesion development is unknown, the gene 
expression of certain angiogenic factors may decrease over time. Further 
investigation is however required to determine the exact roles of angiogenic 
dynamics in periapical disease development.
5.2 The normal human dental pulp – reservoir of 
angiogenic factors (Paper III)
It is mostly upon pulp pathologic conditions that periapical tissues exhibit 
inflammatory disorders. We therefore sought to continue the investigation on the 
presence of VEGF family and receptors in normal dental human pulp. 
The existence of VEGF and VEGFR-2 in well-vascularized pulp has been described 
before [217, 218]. In our study we demonstrate for the first time the presence of 
VEGF-B, -C, -D at gene and protein level in the normal human dental pulp. We 
identified CD68+ macrophages and CD3+ T lymphocytes as the sources of VEGF-A, -
B, -C and -D, as well as VEGFR-2 and -3. Thus, cells involved in the pulp 
immunosurveillance [226] are also the source of angiogenic factors. No ELA-2+
neutrophils or CD19+ B-cells were identified in the analyzed tissue. Other
investigations have also reported the absence of neutrophils and B-lymphocytes from 
normal pulp tissue, which is in accordance with our findings [227, 228]. However, a 
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new study using flow cytometry as method of analysis has identified a small 
percentage of approximately 2% B-lymphocytes, as well as a general population of 
CD16+ granulocytes in dental pulp [229]. This discrepancy of results may be due to 
the technique employed by Gaudin et al. and furthermore, the authors did not use 
specific markers for neutrophils [229].
VEGF-B was only found on immune cells in our analyzed samples. This factor is 
involved in blood ECs and pericyte survival, with no angiogenic activity [230]. It 
seems to be related to metabolic and neuroprotective functions [28-30]. We assume 
that VEGF-B may also exert a protective action on pulpal neuronal and ECs, possibly 
also under inflammatory conditions.
Matsushita et al. found that VEGF-A produced by dental pulp cells acts directly on 
these cells via autocrine mechanisms, promoting chemotaxis and cellular 
differentiation, action which mostly occurs via VEGFR-2 signaling [231].
The presence of the investigated VEGFs and VEGFRs on ECs, immune and stromal 
cells denotes possible cellular autocrine and paracrine communications, which may 
also be involved in vascular activities occurring in the dental pulp. Dental pulp stem 
cells are a known source of VEGF-A [232], however the presence of VEGF-B, -C
and -D on these potent cells remains an open research topic.
We confirm the presence of vessels of angiogenic origin (CD31+) expressing VEGF-
A, -C, -D and VEGFR-2 and -3 in normal dental pulps. Negative immunostaining 
with specific lymphatic markers, such as LYVE-1 and D2-40 exclude the presence of 
lymphatic vascular structures in the analyzed tissue. Even though formerly disputed, 
this is in accordance with another observation stating that human pulp does not 
present with lymphatic vessels [116]. However, fenestrated blood capillaries, a 
known source of VEGFR-3, have been described in the dental pulp [105]. Other 
studies have shown that VEGFR-3 expression is induced in ECs during angiogenesis 
in developing cornea and that it forms heterodimers with VEGFR-2 in blood vessels 
[233, 234]. The important up-regulation of the VEGFR-3 gene encountered in our 
study, as well as its’ roles along with the VEGF-C and -D presence on cells and 
vessels in the normal dental pulp require further investigations.
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In normal human dental pulp sections we commonly found LYVE-1+ macrophages,
as also seen in mouse pulp [115]. In epididymal adipose tissue, LYVE-1+
macrophages play an angiogenic role [235]. This epididymal tissue is highly hypoxic, 
thus promoting increased VEGF-activity via VEGFR-2, which in turn recruits bone-
marrow derived LYVE-1+ macrophages. At gene level, VEGF, VEGFR-1 and
VEGFR-2 were significantly up-regulated in the dental pulp. VEGFR-1 has been 
shown to be necessary for survival of ECs and macrophages [236]. Furthermore, the
inhibition of VEGFR-1 resulted in reduced macrophage recruitment, as well as 
impaired angiogenesis via MCP-1 signaling [237]. These findings may support an 
angiogenic role of macrophages in the dental pulp.
Interestingly, HIF1A, known for its ability to induce VEGF-signaling during hypoxia, 
showed a significant up-regulation in the pulp compared with control PDL, another 
highly vascularized tissue. Additionally, HIF-1 influences self-renewal and 
differentiation of stem cells by specific gene regulation and transcription factors 
important for stem-cell quiescence [238]. It is also known for regulating bone 
formation by osteoblasts [239]. Since the dental pulp rests in a low-oxygen 
environment, it is likely that the level of HIF1A may influence the stem cells numbers 
of the dental pulp and extrapolating its’ known effects on bone development, it may 
also control odontoblast function. A similar role in stem-cell quiescence is 
demonstrated by NFATc1 [240], which also exhibited an increased gene expression in 
the current study. 
Furthermore, genes of the MAPK and Pl3K families, involved in ECs migration and 
survival [241, 242], were also highly expressed in normal dental pulp, fact which 
suggests an intense vascular activity of this tissue. 
Our findings show that the dental pulp is an angiogenic reservoir, with vascular and 
immune cell interplay. However the exact roles of VEGF family members and genes 
involved in VEGF signaling, along with the roles of LYVE-1+ macrophages in the 
dental pulp still require further investigations.
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5.3 The roles of VEGFR-2 and/or -3 signaling in apical 
periodontitis
Our results on the presence of VEGFs and VEGFRs in dental tissues and in periapical 
lesions of endodontic origin raised numerous questions on the action mechanisms of 
these molecules. We aimed at looking into the VEGFR-2 and/or -3 signaling 
pathways during the development of apical periodontitis by individual or 
simultaneous blocking of these receptors. There were two major findings: blocking 
VEGFR-2 increased periapical inflammation characterized by amplified immune cell 
recruitment and inflammatory cytokine levels, while combined inhibition of VEGFR-
2 and -3 showed a decreased inflammatory response.
Lesion sizes increased rapidly during the active phase of development until day 10 
upon single VEGFR-2 and -3 blocking, compared to positive controls (IgG) and 
combined anti-VEGFR-2 and -3 treatments. In the chronic stage of disease progress, 
on day 21, they have reached similar levels in all four experimental groups. Even 
though no statistically significant differences were found between the test groups, 
time was of the essence regarding the overall lesion progression from day 0 to day 21 
within each test group. The strong inflammatory response seen upon VEGFR-2
inhibition with significantly higher amounts of neutrophils and TRAP+ osteoclasts 
may have resulted in rapid lesion growth. In a study conducted on osteopetrotic mice, 
VEGFR-3 was found to participate in osteoclast differentiation, with the inhibition of 
this receptor resulting in a reduction of osteoclasts [243]. We assume that in the 
context of periapical disease, VEGFR-3 signaling may have a direct inhibitory effect 
on osteoclast activity independent of their cellular numbers. After blocking VEGFR-
3, an increased initial resorptive activity occurs, translated as faster lesion size 
expansion until day 10. 
Osteoclasts, immune cells and blood ECs were found positive for both VEGFR-2 and 
-3 in papers I and II. In the current investigation, in order to evaluate the effects of 
VEGFR-2 and/or -3 signaling on these cells, we quantified TRAP+ osteoclasts, Ly-
6.B2+ PMNs and F4/80+ macrophages, along with CD31+ blood vessels within the 
developed periapical lesions. 
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The numbers of PMNs and osteoclasts significantly increased upon VEGFR-2
blocking on day 10, whereas anti-VEGFR-3 treatment and combined inhibition of 
VEGFR-2 and -3 resulted in substantially fewer PMNs and osteoclasts than after
VEGFR-2 blocking. This may indicate that PMN recruitment and osteoclast 
differentiation in apical periodontitis are under VEGFR-2 inhibitory signaling. 
Macrophages seem to be influenced by combined VEGFR-2/-3 signaling, as their
numbers significantly decreased following combined systemic treatment on day 10. 
Blocking VEGFR-2 alone or simultaneous with VEGFR-3 decreased blood vessel 
counts, whereas the opposite effect was noticed under VEGFR-3 inhibition. This
indicates that the intense inflammatory response seen in the VEGFR-2 treatment 
group is independent of angiogenesis. Lymphangiogenesis in the regional draining 
lymph nodes seems to depend on both VEGFR-2 and -3, since an inhibition of the 
process occurred by individual as well as combined blocking of these receptors. The 
intense apical inflammatory reaction that follows the VEGFR-2 inhibition is also seen 
as lymphadenitis of the lymph nodes. 
Blocking both VEGFR-2 and -3 in the current study resulted in reduced periapical 
inflammation and angiogenesis, also seen in a model of corneal inflammation [244].
The same study [244] reports the inhibition of lymphagiogenesis under combined 
VEGFR-2/-3 blocking, which we have also seen in the draining lymph nodes.
The lack of lymphatics in the apical periodontium that we observed in papers I and II 
may result in different outcomes of the current investigation. Inhibition of VEGFR-2
decreased the severity of skin inflammation and arthritis [95, 96]. However, in those 
disease models, lymphangiogenesis does happen and is affected by both VEGFR-2
and -3 [95]. In apical periodontitis, no lymphangiogenesis can take place due to 
absence of lymphatic vessels. In contrast, we also report outcomes from an infectious 
disease with continuous antigenic stimulation, while the used models of skin 
inflammation and arthritis occurred in a sterile manner. This may explain our 
contradictory results.
Immune cells encountered in periapical lesions are the source of highly potent 
cytokines that activate bone resorption. We therefore investigated the expression of a 
wide panel of cytokines and chemokines involved in inflammation in well-established 
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periapical lesions. The results provided evidence for the important role in 
augmentation or attenuation of inflammatory reactions via VEGFR-2 and combined 
VEGFR-2/-3 signaling, respectively.
A tendency to down-regulation of many pro-inflammatory cytokines and chemokines, 
involved in the complex network of osteoclast differentiation and bone resorption, 
such as RANKL, IL-1 , IL-1 , IL-6, TNF , IL-17, MCP-1, MIP-1 , MIP-1 , MIP-2
and RANTES was observed upon combined inhibition of both receptors. 
Furthermore, most cytokines showed highest levels upon VEGFR-2 blocking, 
supportive of the intense inflammatory reaction. Even though IL-1 , IL-1 , TNF or
MCP-1 levels are significantly increased after VEGFR-2 treatment, their pro-
angiogenic effect does not occur, as seen in the low numbers of blood vessels counted 
on day 21. The VEGFR-2 is known as the main angiogenic receptor. The increased 
expression of these cytokines can be attributed to both the intense inflammatory 
immune response and to a compensatory reaction following VEGFR-2 inhibition.
MKC, a chemokine involved in neutrophil chemotaxis, increased in all experimental 
groups. A collaborating effect of MKC with G-CSF has been described with respect 
to PMN mobilization during acute inflammation [245]. G-CSF seems to have 
beneficial roles during inflammatory conditions, as it down-regulates LPS-induced 
TNF production [246]. Our findings show that upon VEGFR-2/-3 blocking, TNF
exhibits lowest values, while MKC and G-CSF are significantly increased. This 
supports the anti-inflammatory and MKC-collaborative effects of G-CSF, but cannot 
explain the intense inflammation occurring upon VEGFR-2 inhibition.
The exact mechanisms through which VEGFR-2 signaling reduces, while 
simultaneous VEGFR-2 and -3 activation boosts inflammatory reactions during 
apical periodontitis is in need of further investigation.
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6. Conclusive remarks
1. The VEGFs-A, -C, - D and VEGFRs- 2 and -3 are well represented on blood 
vessels in normal rat periodontium. Cells lining the bone and on root surface 
as well as cells with fibroblastic appearance express VEGFR-2 and -3 under 
normal conditions.
2. Inducing apical periodontitis in rats augments the presence of cells and vessels 
positive for VEGFs and VEGFRs in the inflamed areas. The sources of VEGF-
A, -C and -D are macrophages and neutrophils. An important finding is that 
multinucleated osteoclasts express VEGFR-2 and -3 in inflamed apical tissue. 
The presence of VEGF family and their receptors on immune cells, blood 
vessels and osteoclasts during development of apical periodontitis suggests 
their implication in periapical disease development with respect to immune 
reactions, bone remodeling and angiogenesis.
3. Macrophages, PMNs, B- and T-lymphocytes, along with blood vessels express 
VEGF-A, -C, -D and VEGFR-2 and -3 in human periapical lesions. Gene 
expression of several pathways involved in VEGF signaling was altered in 
diseased periapical tissue compared with healthy PDL. This suggests ongoing 
vascular remodeling with immune cell implication in human periapical
pathology.
4. In the well-vascularized dental pulp, macrophages and T-lymphocytes are the 
sources of VEGF-A, -B, -C, -D and VEGFR-2 and-3. In accordance with 
previous reports, no PMNs and B-lymphocytes reside in the normal dental 
pulp. While VEGF-B is only found at immune cellular level, the rest of 
investigated factors and receptors are expressed on pulp blood vessels. 
Furthermore, 67 out of 84 investigated genes involved in VEGF signaling 
were altered in normal dental pulp vs PDL. HIF1A and NFATc1 expression is 
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likely induced by hypoxia in the pulp and these probably represent important 
factors for stem-cell quiescence. Thus, the dental pulp represents an 
angiogenic reservoir with high vascular activity and remodeling potential.
5. Our studies confirm that lymphatic vessels are absent from periapical tissues 
and from the dental pulp. Macrophages expressing the lymphatic marker 
LYVE-1 are present in both human normal dental pulp and periapical inflamed 
tissues. Even though their exact role remains to be determined, their main 
activity is assumed to be angiogenic.
6. In a murine model of apical periodontitis we show that VEGFR-2 inhibits, 
while combined VEGFR-2 and -3 signaling enhances periapical inflammation. 
Evidence for this finding is provided by the initial fast growth of the lesion 
sizes along with an increased presence of PMNs and osteoclasts upon 
VEGFR-2 inhibition, while numbers of macrophages, neutrophils and blood 
vessels are lowered after combined VEGFR-2/-3 systemic blocking. 
Furthermore, in the well-established periapical lesions, major pro-
inflammatory cytokines like IL- -
VEGFR-2 systemic treatment. In contrast, blocking both VEGFR-2 and -3
decreases expressions of inflammatory cytokines, significant for RANKL and
MCP-1. We also conclude that lymphangiogenesis in the draining lymph 
nodes seems to be equally dependent on VEGFR-2 and -3.
7. Even though the exact interplay between cells expressing ligands to VEGFR-2
and/or -3 involved in periapical disease pathogenesis still needs further 
investigations, we provide important initial evidence of their signaling 
contribution to periapical disease development. 
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7. Future perspectives
Since our initial investigations for mapping VEGF family members and their 
receptors at protein level are mainly descriptive, a quantification of these molecules 
in animal and human dental tissues should be performed. Both normal and inflamed 
pulp as well as periapical tissues can be subjected to quantification of VEGFs and 
VEGFRs expression by counting immunohistochemically stained structures and by 
use of enzyme-linked immunosorbent assays or flow cytometry analysis of the 
respective tissues. 
We assume that the high gene expression levels of HIF1A and NFATc1 in normal 
dental pulp are important for stem cell quiescence. It has been shown that dental pulp 
stem cells can induce VEGFR-2 dependent angiogenesis [247]. Investigations on the 
expression of all VEGFs and VEGFRs by stem cells in the normal dental pulp could 
provide more information on their possible involvement in pulp angiogenesis.
Pulp repair and revascularization of immature necrotic teeth require angiogenic 
processes. Understanding the molecular mechanisms underlying angiogenesis can 
lead to new therapeutic strategies. It has been previously suggested that topical 
application of VEGF-A enhances pulp neovascularization [248]. Knowing that both 
VEGFR-2 and -3 are present on vessels of angiogenic origin in the dental pulp, tissue 
engineering and possible therapeutic intervention on injured dental pulp could also be 
expanded to VEGF-C and -D.
Since we could not confirm the presence of lymphatic vessels in dental pulp or 
periodontium there are still open questions on the exact roles of VEGF-C, -D and 
their receptors VEGFR-2 and -3, along with their possible angiogenic involvement.
Macrophages expressing LYVE-1, a lymphatic marker, were found both in normal 
human dental pulp, as well as inflamed apical tissue. This implies that they are 
resident cells of the dental tissues, but also recruited at sites of dental inflammation, 
where they may have a role in immune response. Due to the absence of lymphatics in 
the dental pulp and apical periodontium, we assume an angiogenic role of these 
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macrophages. However, information on their kinetics and exact function is still in 
need of further investigation. 
Lymphatic responses were found in the draining lymph nodes in apical periodontitis 
settings. However, the localization of peripheral lymphatic vessels remains unknown. 
Further research is needed to clarify lymphatic mechanisms.
Research on macrophages has focused on the polarization of these cells during 
inflammatory conditions, describing different expression of pro-inflammatory 
cytokines and chemokines by 2 distinct types of macrophages, M1 and M2, and 
accordingly with diverse immune effects [249].  The M1 form expresses pro-
inflammatory, whereas anti-inflammatory cytokines are produced by the M2 subtype. 
In our studies we used antibodies that generically stain cells of monocytic origin. 
Thus, more research is needed in order to understand the macrophage types present in 
dental tissues and their involvement in the pathogenesis of apical periodontitis and 
possibly in vascular remodeling.
In murine apical periodontitis we show that VEGFR-2 reduces, while combined 
VEGFR-2 and -3 signaling increases inflammation. Yet, further investigations are
needed in order to elucidate the exact mechanisms of VEGFR-2 and/or -3 signaling in 
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